【摘要】 目的探讨破血逐瘀法联合依达拉奉治疗急性高血压性脑出血的临床疗效及安全性。方法选择我院2014年5月至2016年1月发病72 h内收治的60例高血压性脑出血患者,随机分为对照组和治疗组各30例,对照组采用常规治疗,治疗组在常规治疗基础上,采用破血逐瘀法联合依达拉奉治疗10 d,比较两组治疗前及治疗后14 d、30 d美国国立卫生研究院卒中量表(NIHSS)评分及脑出血血肿扩大情况。结果两组治疗后14 d脑出血血肿体积比较,治疗组较对照组有明显改善(P<0.05);治疗组NIHSS评分于治疗后第14天较治疗前有明显改善(P<0.05),而对照组治疗前后比较改善不明显(P>0.05);两组治疗后第14天NIHSS评分比较(P>0.05),而两组治疗后第30天NIHSS评分比较(P<0.05);另外,两组治疗后血肿扩大比较未见明显差异(P>0.05)。结论破血逐瘀法联合依达拉奉治疗急性高血压脑出血,能改善患者的神经功能,安全性好。更多还原

【Abstract】 Objective To observe the clinical safety and effects of breaking blood expelling stasis combined with Edaravone on patients with acute hypertensive intracerebral hemorrhage. Methods 60 patients with hypertensive intracerebral hemorrhage within 72 hours admitted in our hospital from May 2014 to January 2016 were included. Then they were divided into control group and treatment group at random and each group had 30 patients. The control group was treated with conventional therapy, and the treatment group was treated with conventional therapy as well as 10 days treatment of breaking blood expelling stasis combined with Edaravone. NIHSS before and 14 days, 30 days after the treatment of these two groups as well as the hematoma enlargement after the treatment had been accessed. Results NIHSS of the treatment group 14 days after the treatment had obvious improvement compared with before therapy(P <0.05), but the control group had not obvious improvement compared with before therapy(P >0.05). Furthermore, we found no significant difference on NIHSS between these two groups after 14 days treatment(P >0.05). However, NIHSS of the treatment group 30 days after the treatment had obvious improvement compared with control group(P <0.05). Moreover the hematoma enlargement did not significantly different between these two groups after the treatment(P >0.05). Conclusion Treating acute hypertensive intracerebral hemorrhage with breaking blood expelling stasis and Edaravone can improve the neurological function, and it is safe for it.更多还原